John Hays
John Hays
Associate Professor, The Ohio State University James Cancer Hospital
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses
JM Lee, JL Hays, CM Annunziata, AM Noonan, L Minasian, JA Zujewski, ...
JNCI: Journal of the National Cancer Institute 106 (6), 2014
Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers
KB Kuchenbaecker, L McGuffog, D Barrowdale, A Lee, P Soucy, S Healey, ...
JNCI: Journal of the National Cancer Institute 109 (7), 2017
The role of PARP inhibitors in the treatment of gynecologic malignancies
RE Reinbolt, JL Hays
Frontiers in oncology 3, 237, 2013
Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target
U Saini, S Naidu, AC ElNaggar, HK Bid, JJ Wallbillich, K Bixel, C Bolyard, ...
Oncogene 36 (2), 168-181, 2017
Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions
DH Moon, JM Lee, AM Noonan, CM Annunziata, L Minasian, N Houston, ...
British journal of cancer 109 (4), 1072-1078, 2013
Akt activation mediates acquired resistance to fibroblast growth factor receptor inhibitor BGJ398
J Datta, S Damodaran, H Parks, C Ocrainiciuc, J Miya, L Yu, EP Gardner, ...
Molecular cancer therapeutics 16 (4), 614-624, 2017
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers
KB Kuchenbaecker, SL Neuhausen, M Robson, D Barrowdale, ...
Breast cancer research 16 (6), 1-27, 2014
Olaparib in the management of ovarian cancer
K Bixel, JL Hays
Pharmacogenomics and personalized medicine 8, 127, 2015
Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma
MA Krook, A Lenyo, M Wilberding, H Barker, M Dantuono, KM Bailey, ...
Molecular cancer therapeutics 19 (3), 847-857, 2020
Use of targeted therapeutics in epithelial ovarian cancer: a review of current literature and future directions
MH Vetter, JL Hays
Clinical Therapeutics 40 (3), 361-371, 2018
Mixed adeno-neuroendocrine carcinoma: an aggressive clinical entity
S Brathwaite, J Rock, MM Yearsley, T Bekaii-Saab, L Wei, WL Frankel, ...
Annals of surgical oncology 23 (7), 2281-2286, 2016
A microfluidic chip enables isolation of exosomes and establishment of their protein profiles and associated signaling pathways in ovarian cancer
KDP Dorayappan, ML Gardner, CL Hisey, RA Zingarelli, BQ Smith, ...
Cancer research 79 (13), 3503-3513, 2019
A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety
JL Hays, G Kim, A Walker, CM Annunziata, JM Lee, J Squires, N Houston, ...
Molecular and clinical oncology 1 (3), 565-569, 2013
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
JM Lee, JL Hays, VL Chiou, CM Annunziata, EM Swisher, MI Harrell, ...
Oncotarget 8 (45), 79175, 2017
Appendiceal mixed adeno-neuroendocrine carcinoma: a population-based study of the Surveillance, Epidemiology, and End Results registry
S Brathwaite, MM Yearsley, T Bekaii-Saab, L Wei, CR Schmidt, ...
Frontiers in oncology 6, 148, 2016
Distinct functions of retinoic acid receptor beta isoforms: implications for targeted therapy
CB Swift, JL Hays, WJ Petty
Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug …, 2008
Oligomerization-induced modulation of TPR-MET tyrosine kinase activity
JL Hays, SJ Watowich
Journal of Biological Chemistry 278 (30), 27456-27463, 2003
Feasibility and safety of sequential research‐related tumor core biopsies in clinical trials
J Lee, JL Hays, AM Noonan, J Squires, L Minasian, C Annunziata, ...
Cancer 119 (7), 1357-1364, 2013
Autophagy induction results in enhanced anoikis resistance in models of peritoneal disease
JL Chen, J David, D Cook-Spaeth, S Casey, D Cohen, K Selvendiran, ...
Molecular Cancer Research 15 (1), 26-34, 2017
PARP inhibition and gynecologic malignancies: a review of current literature and on-going trials
SM Crafton, K Bixel, JL Hays
Gynecologic oncology 142 (3), 588-596, 2016
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20